VMB-100

PRESS RELEASE | Basel, Switzerland, Dezember 5, 2023 Versameb AG Names Dr. Alexandre LeBeaut as Chair of the Board of Directors Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that its Board of Directors has unanimously appointed of Dr. Alexandre LeBeaut, MD as Chairman of the Board, effective immediately. Dr. LeBeaut has over two decades of global R&D leadership experiences, successfully bringing multiple medicines to market in immunology, oncology, gastroenterology, cardio-metabolic and infectious diseases. Dr Klaas Zuideveld, Chief Executive Officer of Versameb, said: “Dr. LeBeaut’s has been a valuable member of our board since July 2023 and has extensive experience that has been instrumental in securing the recent Investigational New Drug clearance by the FDA of our lead candidate, VMB-100, for the treatment of Stress Urinary Incontinence (SUI). We look forward to his continued guidance as Chairman of Versameb’s Board of Directors, particularly ahead of initiating our first-in-human clinical study of VMB-100 as a therapeutic option for patients suffering SUI in the first half of 2024.” Dr. Alexandre LeBeaut, new Chairman of the Board of Directors of Versameb, commented: “I am honored to take this responsibility as Chair of Versameb’s board at such a pivotal time in company’s growth trajectory. Through the development of its unique and proprietary VERSagile platform the company can target the biology of diseases with unmet medical needs and to have the potential to transform patients’ lives. This is particularly relevant for VMB-100 which is set to enter Phase 2a open label study for treatment of SUI in 2024.” Dr. LeBeaut is a seasoned R&D executive with tremendous leadership experience at global biopharmaceutical companies including Schering-Plough Research Institute, Novartis Pharmaceuticals, Sanofi, Axcan Pharmaceuticals and Bluebird Bio. Dr. LeBeaut served as Executive Vice-President R&D and Chief Scientific Officer at Ipsen in the US, leading R&D global strategies and execution contributing to the definition of 5 new molecular entities and the approval of 10 major indications globally. Most recently, Dr. LeBeaut was CEO of the Institute for Advanced Clinical Trials for Children and served as an independent director of Vifor Pharma. He is currently an Independent Director of Calypso Biotech (Geneva, Switzerland), OSE Immunotherapeutics (Paris, France) and ImmunoRx Pharma (Wilmington, DE). About VMB-100 VMB-100 is an intramuscularly locally delivered, sequence engineered messenger ribonucleic acid (mRNA) encoding for human insulin-like growth factor-1 (IGF-1) under investigation for the treatment of stress urinary incontinence (SUI). VMB-100 has the potential to become first-and best-in-class in sustained muscle regeneration following short-term treatment. In preclinical studies, it has been demonstrated that VMB-100 induced the expression of IGF-1 levels in human muscle cells. In animals models of SUI, VMB-100 accelerated regeneration of the urinary sphincter muscle and restored urinary sphincter function after a single dose of treatment. Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study of VMB-100 in female subjects with moderate stress urinary incontinence in the first half of 2024. About Stress Urinary Incontinence Stress urinary incontinence is a common condition amongst women in which a leakage of urine occurs during moments of physical activity due to a weakened urinary sphincter muscle. SUI is the most common type of urinary incontinence, affecting 86% of incontinent women. Despite the prevalence of SUI, there are currently no approved pharmacological therapies available in the United States. Current standard of care protocol includes short-term solutions like pelvic floor therapy or a highly invasive surgical procedure in which a sling is permanently implanted into the urethra or bladder neck. About Versameb AG Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational since 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at www.versameb.com as well as on LinkedIn. Contact for media enquiries: Versameb Dr Klaas Zuideveld, CEO ir@versameb.com Stern Investor Relations, Inc. Janhavi Mohite +1 212-362-1200 janhavi.mohite@sternir.com Optimum Strategic Communications Mary Clark, Charlotte Hepburn-Scott, Zoe Bolt, Katie Flint Tel: +44 (0)20 3882 9621 versameb@optimumcomms.com DOWNLOAD PDF – English

BASEL, Switzerland, Nov. 16, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application of VMB-100, a potency enhanced messenger ribonucleic acid (mRNA) encoding human insulin-like growth factor-1 (IGF-1), for the treatment of stress urinary incontinence (SUI). Following this clearance, Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study in the first half of 2024. The study will evaluate the safety, tolerability, and efficacy of VMB-100 in female subjects with stress urinary incontinence, a highly common condition resulting in involuntary leakage of urine due to a weakened urinary sphincter muscle. "The IND clearance by the FDA represents a significant milestone for the VMB-100 development program and for Versameb," said Klaas Zuideveld, Chief Executive Officer of Versameb AG. "This brings us a step closer to providing an effective therapeutic option to patients suffering from SUI. Our proprietary VERSagile platform is uniquely designed to improve potency of mRNA therapeutics and we believe VMB-100 can potentially become a game changer for SUI treatment. We look forward to initiating this trial in the first half of 2024 to evaluate the potential clinical benefits of VMB-100 in SUI." "Stress urinary incontinence significantly impacts the quality of life of millions of women globally and is a major unmet medical need with no approved therapeutics available currently," said Professor Roger Dmochowski, Chief Medical Officer of Versameb AG. "IGF-1 plays a key role in promoting muscle regeneration and re-establishment of muscle function. We believe VMB-100 has the potential to fill the current therapeutic gap as a first-in-class mRNA therapy that can restore muscle function and thereby effectively treat incontinence." About VMB-100 VMB-100 is an intramuscularly locally delivered, sequence engineered messenger ribonucleic acid (mRNA) encoding for human insulin-like growth factor-1 (IGF-1) under investigation for the treatment of stress urinary incontinence (SUI). VMB-100 has the potential to become first-and best-in-class in sustained muscle regeneration following short-term treatment. In preclinical studies, it has been demonstrated that VMB-100 induced the expression of IGF-1 levels in human muscle cells. In animals models of SUI, VMB-100 accelerated regeneration of the urinary sphincter muscle and restored urinary sphincter function after a single dose of treatment. Versameb plans to launch a Phase 2a open label, first-in-human dose ascending study of VMB-100 in female subjects with moderate stress urinary incontinence in the first half of 2024. About Stress Urinary Incontinence Stress urinary incontinence is a common condition amongst women in which a leakage of urine occurs during moments of physical activity due to a weakened urinary sphincter muscle. SUI is the most common type of urinary incontinence, affecting 86% of incontinent women. Despite the prevalence of SUI, there are currently no approved pharmacological therapies available in the United States. Current standard of care protocol includes short-term solutions like pelvic floor therapy or a highly invasive surgical procedure in which a sling is permanently implanted into the urethra or bladder neck. About Versameb AG Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational since 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb's proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts. The pipeline includes lead candidate programs in stress urinary incontinence (SUI), solid tumors and rare diseases. Versameb is working towards the completion of a first in-human proof-of-concept clinical study while advancing its platform. More information on Versameb can be found at as well as on LinkedIn. SOURCE Versameb